e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
82.07
USD
+2.05 (+2.56%)
Official Closing Price
Updated: 7:48 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
January 19, 2021
Arrowhead to release earnings and hold conference call on February 4 2021
From
Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
December 07, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
From
Business Wire News Releases
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
December 02, 2020
From
GlobeNewswire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
November 30, 2020
Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop
From
Business Wire News Releases
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
November 25, 2020
Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited
From
Business Wire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
November 23, 2020
Arrowhead announced financial results for its fiscal year ended September 30, 2020
From
Business Wire News Releases
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
November 13, 2020
Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association
From
Business Wire News Releases
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
November 13, 2020
Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
November 09, 2020
Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
November 04, 2020
Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
November 02, 2020
Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings
From
Business Wire News Releases
Thinking about trading options or stock in Arrowhead Pharmaceuticals, Nio Inc, Raven Industries, Apple, or Carnival Corp?
October 15, 2020
InvestorsObserver issues critical PriceWatch Alerts for ARWR, NIO, RAVN, AAPL, and CCL.
From
PR Newswire
Thinking about trading options or stock in General Electric, Roku, CareDx Inc, Arrowhead Pharmaceuticals, or Eli Lilly?
October 08, 2020
InvestorsObserver issues critical PriceWatch Alerts for GE, ROKU, CDNA, ARWR, and LLY.
From
PR Newswire
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
October 08, 2020
Takeda and Arrowhead announced a collaboration and licensing agreement to develop ARO-AAT, a Ph. 2 investigational RNAi therapy to treat AATLD.
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
September 30, 2020
Arrowhead to participate in Chardan Genetic Medicines Conference
From
Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
September 24, 2020
Arrowhead reports inducement grants
From
Business Wire News Releases
Thinking about trading options or stock in Arrowhead Pharmaceuticals, United Parcel Service, MGM Resorts, Moderna, or Microsoft?
September 16, 2020
InvestorsObserver issues critical PriceWatch Alerts for ARWR, UPS, MGM, MRNA, and MSFT.
From
PR Newswire
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
September 16, 2020
Arrowhead positive interim 24-week liver biopsy clinical trial results for ARO-AAT in alpha-1 antitrypsin deficiency improves Key Parameters
From
Business Wire News Releases
Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
September 08, 2020
Arrowhead appoints veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
September 08, 2020
Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020
From
Business Wire News Releases
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
August 31, 2020
Arrowhead Pharmaceuticals positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 at ESC Congress
From
Business Wire News Releases
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
August 28, 2020
Arrowhead and Janssen present Phase clinical data on hepatitis B treatment JNJ-3989 at EASL International Liver Congress 2020
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
August 18, 2020
Arrowhead Pharmaceuticals to present at August 2020 conferences
From
Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
August 18, 2020
Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma
From
Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
August 11, 2020
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
From
Business Wire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
August 05, 2020
Arrowhead Pharmaceuticals reports fiscal Q3 2020 earnings results and hosts conference call
From
Business Wire News Releases
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
July 29, 2020
Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA
From
Business Wire News Releases
Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 28, 2020
Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibrosis
From
Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
July 24, 2020
Arrowhead reports inducement grants
From
Business Wire News Releases
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 09, 2020
Arrowhead Pharma will host a KOL webinar on ARO-ENaC for treatment of cystic fibrosis
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.